Cipla gets 6 observations from USFDA for Goa plant

29 Aug 2022 Evaluate

Cipla has received 6 observations with some referencing to the observations made during the September 2019 inspection, for its Goa plant. There are no data integrity (DI) observations. The company will work closely with the USFDA and is committed to address these within the stipulated time.

The USFDA had inspected company's Goa plant during August 16-26, 2022. Earlier the USFDA had inspected the said facility in September 2019 and the issued warning letter in February 2020.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1491.40 -3.00 (-0.20%)
30-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.60
Dr. Reddys Lab 1265.95
Cipla 1491.40
Zydus Lifesciences 901.30
Lupin 2081.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×